Effect of BNP (Brain Natriuretic Peptides) on Endothelial Dysfunction Induced by Coronary Angioplasty

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2010 by The Baruch Padeh Medical Center, Poriya.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
The Baruch Padeh Medical Center, Poriya
ClinicalTrials.gov Identifier:
NCT00262574
First received: December 6, 2005
Last updated: August 8, 2011
Last verified: December 2010

December 6, 2005
August 8, 2011
July 2005
April 2012   (final data collection date for primary outcome measure)
FMD [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]
FMD-flow mediated dilatation
Complete list of historical versions of study NCT00262574 on ClinicalTrials.gov Archive Site
Not Provided
  • blood level of ET-I ,
  • blood level of proBNP ,
  • and of BNP ,
  • inflammation markers
Not Provided
Not Provided
 
Effect of BNP (Brain Natriuretic Peptides) on Endothelial Dysfunction Induced by Coronary Angioplasty
Phase 4 Study of Patients Receiving BNP or NTG (IV) During Angioplasty, Re-examined 24 Hours Later Using the Flow-mediated Brachial Artery Dilation Study, and Blood Assays for Pro BNP and ET1

Patients receiving BNP or nitroglycerin (IV) during the angioplasty procedure. 24 h after the procedure, vascular reactivity will be re-examined using the brachial artery flow-mediated dilatation study. Blood assays for ET-1, pro-BNP, and various inflammatory markers will be checked before and 24 h after the procedure. It is our hypothesis that endothelial function will be better in the BNP treated patients compared to the NTG treated patients

Not Provided
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Outcomes Assessor)
Primary Purpose: Supportive Care
Coronary Artery Disease
Drug: Nesiritide,
PCI
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
500
June 2013
April 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:coronary artery disease -

Exclusion Criteria:CHF and/or reduced LV function, or renal failure with Creatinine >2mg%

-

Both
Not Provided
No
Contact: Yonathan Hasin, prof. 97246652649 yhasin@poria.health.gov.il
Contact: Diab gahnim, Dr
Israel
 
NCT00262574
20020474-Hasin-BNP.CTIL
No
prof yonathan hasin, Israell health ministry
The Baruch Padeh Medical Center, Poriya
Not Provided
Principal Investigator: Mina Arinos Ministry of Health, Israel
The Baruch Padeh Medical Center, Poriya
December 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP